Literature DB >> 12903843

Preclinical models for chemoprevention of colon cancer.

Eugene W Gerner1, Natalia A Ignatenko, David G Besselsen.   

Abstract

Colon cancer is the second leading cause of cancer incidence and death in the USA in 2002. Specific genetic defects have been identified which cause hereditary colon cancers in humans. In addition, a number of intestinal luminal risk factors for colon cancer have been described. This information has been exploited to develop experimental cell and rodent models which recapitulate features of human colon cancer. In this chapter, we will discuss the strengths and limitations of these models to further our understanding of basic mechanisms of colon carcinogenesis and to develop strategies for colon cancer chemoprevention.

Entities:  

Mesh:

Year:  2003        PMID: 12903843     DOI: 10.1007/978-3-642-55647-0_6

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  5 in total

1.  Association between 6-n-propylthiouracil (PROP) bitterness and colonic neoplasms.

Authors:  Marc D Basson; Linda M Bartoshuk; Susan Z Dichello; Lisa Panzini; James M Weiffenbach; Valerie B Duffy
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

2.  Fluorescence-based surface magnifying chromoendoscopy and optical coherence tomography endoscope.

Authors:  R Andrew Wall; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2012-08       Impact factor: 3.170

Review 3.  Targeting polyamines and inflammation for cancer prevention.

Authors:  Naveen Babbar; Eugene W Gerner
Journal:  Recent Results Cancer Res       Date:  2011

4.  Polyamine metabolism is sensitive to glycolysis inhibition in human neuroblastoma cells.

Authors:  M Victoria Ruiz-Pérez; Miguel Ángel Medina; José Luis Urdiales; Tuomo A Keinänen; Francisca Sánchez-Jiménez
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

Review 5.  Novel translational strategies in colorectal cancer research.

Authors:  Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.